Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2005 1
2006 3
2007 2
2008 6
2009 7
2010 7
2011 7
2012 2
2013 2
2014 3
2015 3
2017 2
2018 2
2019 2
2020 2
2021 1
2022 3
2023 8
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Results by year

Filters applied: . Clear all
Page 1
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Cheng Y, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Osypchuk Y, Sinielnikov I, Yang TS, Liang X, Chen C, Wang L, Cheng AL, Kaseb A, Vogel A; CARES-310 Study Group. Qin S, et al. Lancet. 2023 Sep 30;402(10408):1133-1146. doi: 10.1016/S0140-6736(23)00961-3. Epub 2023 Jul 24. Lancet. 2023. PMID: 37499670 Clinical Trial.
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study.
Harding JJ, Fan J, Oh DY, Choi HJ, Kim JW, Chang HM, Bao L, Sun HC, Macarulla T, Xie F, Metges JP, Ying J, Bridgewater J, Lee MA, Tejani MA, Chen EY, Kim DU, Wasan H, Ducreux M, Bao Y, Boyken L, Ma J, Garfin P, Pant S; HERIZON-BTC-01 study group. Harding JJ, et al. Lancet Oncol. 2023 Jul;24(7):772-782. doi: 10.1016/S1470-2045(23)00242-5. Epub 2023 Jun 2. Lancet Oncol. 2023. PMID: 37276871 Clinical Trial.
Radiation Therapy and Malignant Fistulae of Anorectal Cancers.
Koroulakis AI, Molitoris JK, Sullivan M, Jiang Y, Hausner PF, Hanna N, Bafford A, Miller RC, Regine WF. Koroulakis AI, et al. Among authors: jiang y. Pract Radiat Oncol. 2022 Nov-Dec;12(6):e517-e521. doi: 10.1016/j.prro.2022.06.002. Epub 2022 Jun 17. Pract Radiat Oncol. 2022. PMID: 35718072 Review.
The use of nanoparticulates to treat breast cancer.
Tang X, Loc WS, Dong C, Matters GL, Butler PJ, Kester M, Meyers C, Jiang Y, Adair JH. Tang X, et al. Among authors: jiang y. Nanomedicine (Lond). 2017 Oct;12(19):2367-2388. doi: 10.2217/nnm-2017-0202. Epub 2017 Sep 4. Nanomedicine (Lond). 2017. PMID: 28868970 Free PMC article. Review.
Advances in the Pharmacologic Treatment of Hepatocellular Carcinoma.
Bhayani NH, Jiang Y, Hamed O, Kimchi ET, Staveley-O'Carroll KF, Gusani NJ. Bhayani NH, et al. Among authors: jiang y. Curr Clin Pharmacol. 2015;10(4):299-304. doi: 10.2174/1574884710666151020100059. Curr Clin Pharmacol. 2015. PMID: 26548906 Review.
DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinoma.
Kirk AM, Crawford JC, Chou CH, Guy C, Pandey K, Kozlik T, Shah RK, Chung S, Nguyen P, Zhang X, Wang J, Bell M, Mettelman RC, Allen EK, Pogorelyy MV, Kim H, Minervina AA, Awad W, Bajracharya R, White T, Long D Jr, Gordon B, Morrison M, Glazer ES, Murphy AJ, Jiang Y, Fitzpatrick EA, Yarchoan M, Sethupathy P, Croft NP, Purcell AW, Federico SM, Stewart E, Gottschalk S, Zamora AE, DeRenzo C, Strome SE, Thomas PG. Kirk AM, et al. Among authors: jiang y. Cell Rep Med. 2024 Mar 19;5(3):101469. doi: 10.1016/j.xcrm.2024.101469. Cell Rep Med. 2024. PMID: 38508137 Free PMC article.
63 results